Eli Lilly Shares Rise 0.42% as Trading Volume Plummets 41.29% to $2.57 Billion Ranking 29th Amid FDA Oral Drug Decision and Zepbound Sales Woes

Market Snapshot

Eli Lilly (LLY) closed March 23, 2026, with a 0.42% gain, trading at $913.46. Despite the positive price movement, the stock’s trading volume declined sharply by 41.29% to $2.57 billion, ranking 29th in market activity for the day. The muted volume suggests limited short-term investor engagement, contrasting with the 0.75% rise in its share price. Analysts note that the stock remains 36.9% below its estimated fair value and 25% below the $1,209 analyst consensus target, reflecting ongoing valuation concerns despite its long-term growth potential.

Key Drivers

Eli Lilly’s stock performance and strategic positioning are shaped by a confluence of regulatory, competitive, and operational factors. The most immediate catalyst is the pending FDA decision on its oral weight loss drug, orforglipron, which could redefine the company’s obesity portfolio. The drug, currently under review, is central to Lilly’s strategy to diversify beyond injectable therapies and capture a broader patient base. The company’s $3 billion investment in China to manufacture orforglipron locally further underscores its ambition to scale production and tap into the Asia-Pacific market, a region expected to drive global demand for weight management treatments.

However, recent sales data for Lilly’s flagship drug Zepbound (tirzepatide) has raised concerns. Third-quarter 2024 revenue for Zepbound fell short of expectations, with $1.26 billion in sales versus a projected $1.76 billion. Executives attributed this to wholesalers reducing inventory levels, but the underperformance has fueled market skepticism about demand sustainability. This contrasts with Novo Nordisk’s Wegovy, which reported a 79% year-on-year sales increase in the same period, reinforcing its dominance and highlighting the competitive pressures facing Lilly.

The broader weight loss drug market remains a key growth vector, with institutions forecasting a $100 billion market size by 2030. Lilly’s pipeline advancements, including the GLP-1/GIP/GCG triple agonist Retatrutide and the oral GLP-1R agonist orforglipron, position it to compete in this expanding space. Retatrutide’s Phase 3 results, showing up to 16.8% weight loss, and the planned Q2 2026 FDA decision for orforglipron provide long-term upside. Nevertheless, challenges persist: institutional investors have raised mixed signals, with some hedge funds increasing stakes while others cut holdings, reflecting divergent views on valuation and risk.

Legal and operational risks also weigh on the stock. A multibillion-dollar class-action lawsuit over Actos’ bladder cancer risks remains unresolved, complicating Lilly’s legal landscape. Additionally, the company faces supply chain bottlenecks, including cold chain constraints and inventory management issues, which have dampened sales for Zepbound and Mounjaro. While Lilly plans to launch demand-stimulating initiatives, including direct-to-consumer advertising, these efforts are yet to materialize in near-term results.

Institutional confidence remains a mixed signal. GAMMA Investing LLC increased its stake in LLY by 27% in Q4 2025, valuing its position at $23.45 million, while Vanguard and State Street Corp also boosted holdings. However, recent analyst downgrades and a “Moderate Buy” consensus rating indicate caution, with price targets averaging $1,221.44. The stock’s 9.8% 30-day return decline and 11x forward P/E multiple further reflect short-term volatility, despite the company’s long-term pipeline and market expansion bets.

Strategic Outlook

Eli Lilly’s ability to navigate these dynamics will determine its trajectory. The FDA’s decision on orforglipron and the success of Retatrutide in late-stage trials could reinvigorate investor sentiment, particularly if the company maintains its first-mover advantage in oral therapies. Meanwhile, its China investment and manufacturing expansion signal a strategic pivot to global markets, aligning with the projected growth in obesity treatments. However, the company must address near-term challenges, including inventory management, litigation risks, and competitive pressures from Novo Nordisk and emerging players. For now, the market remains divided, balancing optimism over long-term potential against skepticism about execution and valuation.